ProfileGDS5678 / 1416302_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 87% 87% 86% 85% 88% 89% 90% 87% 87% 87% 87% 88% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7290588
GSM967853U87-EV human glioblastoma xenograft - Control 26.7158687
GSM967854U87-EV human glioblastoma xenograft - Control 36.719387
GSM967855U87-EV human glioblastoma xenograft - Control 46.7262486
GSM967856U87-EV human glioblastoma xenograft - Control 56.3962785
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6721388
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8227389
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1549890
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6040887
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.713287
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6549687
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7035987
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8203288
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2367784